Chemours Co
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
CC$13.48+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Interim Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(107) | $(338) |
| Adjustments to reconcile net loss to cash provided by operating activities: | ||
| Depreciation and amortization | 239 | 259 |
| Gain on sales of assets and businesses | (316) | (8) |
| Equity in earnings of affiliates, net | (20) | (23) |
| Loss on extinguishment of debt | 11 | — |
| Amortization of debt issuance costs and issue discounts | 8 | 9 |
| Deferred tax provision | 228 | 82 |
| Asset-related charges | 1 | 27 |
| Stock-based compensation expense | 18 | 17 |
| Net periodic pension income | (2) | (1) |
| Defined benefit plan contributions | (1) | (2) |
| Other operating charges and credits, net | (4) | 19 |
| Decrease (increase) in operating assets: | ||
| Accounts and notes receivable, net | (223) | (163) |
| Inventories and other current operating assets | 76 | (76) |
| Other non-current operating assets | 65 | 70 |
| (Decrease) increase in operating liabilities: | ||
| Accounts payable | 32 | (79) |
| Other current operating liabilities | 59 | 92 |
| Other non-current operating liabilities | 199 | 242 |
| Cash provided by operating activities | 263 | 127 |
| Cash flows from investing activities | ||
| Purchases of property, plant, and equipment | (144) | (168) |
| Proceeds from life insurance policies | 1 | — |
| Proceeds from sales of assets and businesses | 342 | 7 |
| Foreign exchange contract settlements, net | (8) | (3) |
| Other investing activities | (3) | 1 |
| Cash provided by (used for) investing activities | 188 | (163) |
| Cash flows from financing activities | ||
| Proceeds from issuance of debt | 700 | 95 |
| Debt repayments | (1,028) | (119) |
| Payments on finance leases | (8) | (12) |
| Payments of debt issuance cost | (10) | (4) |
| Proceeds from supplier financing program | 53 | 64 |
| Payments to supplier financing program | (51) | (70) |
| Proceeds from exercised stock options, net | 3 | — |
| Payments related to tax withholdings on vested stock awards | (2) | (1) |
| Payments of dividends to the Company's common shareholders | (39) | (63) |
| Debt extinguishment payments | (6) | — |
| Other financing activities | 17 | 21 |
| Cash used for financing activities | (371) | (89) |
| Effect of exchange rate changes on cash, cash equivalents, restricted cash and restricted cash equivalents | (3) | 27 |
| Increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents | 77 | (98) |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at January 1, | 724 | 763 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at September 30, | $801 | $665 |
| Supplemental cash flows information | ||
| Non-cash investing and financing activities: | ||
| Purchases of property, plant, and equipment included in accounts payable | $40 | $28 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.